OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

February 13th 2020

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Dr. Berger on Chemotherapy Delivery Options in Ovarian Cancer

February 13th 2020

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Dr. Andreadis on Antibody-Drug Conjugates in DLBCL

February 13th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.

Dr. Simeone on Impact of PARP Inhibitors on Pancreatic Cancer

February 13th 2020

Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.

Optimal Testing Methods in Ovarian Cancer

February 12th 2020

Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.

Dr. Bardia on the Clinical Utility of Liquid Biopsies in Breast Cancer

February 12th 2020

Aditya Bardia, MD, MPH, discusses the clinical utility of liquid biopsies in breast cancer.

Dr. Agarwal on Drug Development in Metastatic Castration-Sensitive Prostate Cancer

February 12th 2020

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.

Dr. Lin on CNS-Specific Outcomes With Neratinib in HER2+ Breast Cancer

February 12th 2020

Nancy Lin, MD, discusses central nervous system–specific outcomes with neratinib (Nerlyx) in HER2-positive breast cancer.

Dr. Mesa on New Trials and Agents in the Myelofibrosis Pipeline

February 12th 2020

Ruben A. Mesa, MD, discusses new trials and agents in the pipeline in myelofibrosis.

Dr. McDermott on Toxicities of Immunotherapy Combinations in RCC

February 12th 2020

David F. McDermott, MD, discusses the toxicities associated with immunotherapy combinations in renal cell carcinoma.

Dr. Paul on the Role of Carfilzomib in Relapsed/Refractory Multiple Myeloma

February 12th 2020

Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Lynce on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

February 12th 2020

Filipa Lynce, MD, discusses the FDA approval of atezolizumab plus nab-paclitaxel for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1

Dr. Abou-Alfa on Progress Made in Hepatocellular Carcinoma

February 11th 2020

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the progress that has been made in the treatment of patients with hepatocellular carcinoma (HCC).

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

February 11th 2020

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.

Dr. Copeland on the Use of PARP Inhibitors in Ovarian Cancer

February 11th 2020

Larry J. Copeland, MD, professor, Obstetrics & Gynecology, College of Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the use of PARP inhibitors in ovarian cancer.

Dr. Siddiqi on the Results of the TRANSCEND CLL 004 Trial in CLL

February 11th 2020

Tanya Siddiqi, MD, discusses the results of the TRANSCEND CLL 004 trial.

Dr. Ramakrishnan on Use of CAR T-Cell Therapy in MCL

February 11th 2020

Praveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).

Dr. Atrash on Investigational Combinations With Venetoclax in Relapsed/Refractory Multiple Myeloma

February 11th 2020

Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

Dr. Pal on the Potential Use of PARP Inhibitors in RCC

February 11th 2020

Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.

Dr. Vusirikala on the Role of Transplant in ALL

February 11th 2020

Madhuri Vusirikala, MD, discusses the role of transplant in acute lymphoblastic leukemia.